The Cost Of Stem Cell Therapy And Why It’s So Expensive …

How much is stem cell therapy? As stated by CBC Canada,the cost of stem cell therapy is $5,000 to $8,000per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher. Our May 2018 poll found that stem cell treatments can cost as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of theclinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.

In this article:

Stem cell therapy is the use of living cells as therapeutics to treat disease or injury. Read on to learn about the cost requirements of these procedures.

CBC Canadas pricing involves Cell Surgical Network (CSN) following its protocol to remove fat tissue and process it before re-injecting [adipose-derived stem cells] either directly or intravenously into the same patient. Unfortunately, the U.S. FDA and Department of Justice (DOJ) sent this network of stem cell treatment providers a permanent injunction notice in May 2018. Therefore, patients should not seek treatments from the group at this time.Although Cell Surgical Network (CSN) is based in California, it has a network of approximately 100 U.S. treatment centers. They also have three Canadian clinics located in Vancouver, Sudbury,andKamloops.

The controversy such as the one above stirs up questions about the safety of stem cell procedures. Anyone considering stem cell therapy from any tissue or source will benefit from understanding the possible consequences of stem cell therapy and the factors driving costs.

For the patient, a stem cell transplant involves multiple steps, including:

There are also real costs for the doctors who provide stem cell treatments. They have overhead costs, including:

There is also time and expertise required toperform the procedure and offer post-operative care. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivery technologies.

Stem cell treatment has gained more and more traction over the last decade. It has been helped along by considerable advances in research. In 2017, the number of scientific publications about stem cells surpassed 300,000. The number of stem cell clinical trials has also surpassed4,600 worldwide.

However, stem cell therapy is still expensive. Among the cheapest and easiest options is to harvest adipose-derived stem cells (ADSCs) those that exist in adult fat layers and re-deliver them to the patient. Unlike harvesting from bone marrow or teeth, providers can feasibly remove fat, separate stem cells, then re-inject them into a patient the same day. This approach is typically less expensive than those that require more invasive procedures for harvesting. Because of its practicality in terms of cost, it has become a common approach to stem cell treatment.

Relatively easy harvesting stilldoesnt translate to inexpensive cost, although some are certainly more affordable than others. For orthopedic conditions, the costof stem cell therapy is typically lower, averaging between $5,000 and $8,000. Examples of these types of medical conditions include:

Note that these prices are typically out-of-pocket costs paid by the patientbecause most insurance companies will not cover them. They are considered experimental and unapproved by the FDA. This means patients needing stem cell treatment will need to use their own savings.

Although fat is a frequently utilized source for stem cells, it is also possible for physicians to utilize stem cells from bone marrow. Regenexx provides this service in the U.S. and Cayman Islands. With theRegenexxstem cell injection procedure, a small bone marrow sample is extracted through a needle, and blood is drawn from a vein in the arm. These samples are processed in a laboratory, and the cells it contains are injected into an area of the body that needs repair. On June 19, 2018, ACAP Health, a leading provider in innovative, clinical-based solutions partnered with Regenexx to reduce high-cost musculoskeletal surgeries.ACAP Health is a national leader in employer healthcare expense reduction. It is one of the first healthcare groups to partner with a stem cell treatment group to support insurance coverage to patients.

A recent Twitter poll conducted by BioInformant reported that, on average, patients can expect to spend $25,000 or more on stem cell therapies. According to the poll,

Most likely, those paying lower stem cell treatment costs under $5,000 were pursuing treatment for orthopedic or musculoskeletal conditions. In contrast, those paying higher treatment costs were likely getting treated for systemic or more complex conditions, such as diabetes, multiple sclerosis (MS), neurodegenerative diseases (such as Alzheimers disease or dementia), psoriatic arthritis, as well as the treatment for autism.

In the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes blood drawn from a patient can cost as little as $1,500. However, protocols that utilize a bone marrow or adipose (fat) tissue extraction can run as much as $15,000 $30,000. This is because bone marrow extraction is an invasive procedure that requires a penetrating bone and adipose tissue extraction requires a medical professional trained in liposuction.

For treatments that require a systemic or whole-body approach, the cost tends to be in the higher range, often averaging from $20,000 to $30,000. Examples of the diseases or conditions requiring this type of stem cell treatment include:

These higher costs reflect the complexity of treating these patients and the fact that multiple treatments are often required.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert, theStem Cell Institutein Panama is one of the worlds most trusted adult stem cell therapy centers. Over the past 12 years, the center has performed more than10,000 procedures, making it a widely recognized destination for stem cell treatments.

Working in collaboration with universities and physicians worldwide, its stem cell treatment protocols utilize combinations of allogeneic human umbilical cord blood stem cells and autologous bone marrow stem cells to treat a wide variety of conditions.

A reader of BioInformant was recently treated for psoriatic arthritis at the Stem Cell Institute in Panama in early 2018. The price of his stem cell treatment was $22,000. With travel and lodging included, the total expenses were approximately $30,000.

Because of its proximity to the U.S., Mexico is increasingly becoming a destination for medical tourism.Before choosing a stem cell treatment provider in Mexico, ensure the clinic is fully authorized by COFEPRIS, the Mexican equivalent to the FDA.

One patient who recently shared stem cell treatment quotes with BioInformant found that the treatment for glycogen storage disease, a metabolic disorder that often onsets in infancy and continues into adulthood, would cost $23,900 throughGIOSTAR Mexico.

In contrast, the patient was quoted$33,000 throughCelltex, a U.S.-based company that treats patients in Cancun, Mexico.Celltex follows FDA regulations concerning the export of cells to Mexico and is compliant with the standards and procedures of COFEPRIS. Celltex also has an alliance with a certified hospital in Mexico, which is approved to receive cells and administer them to patients by a licensed physician.

In contrast, the patient was quoted $10,000 from Stem Cell Therapy of Las Vegas and Med Spa, an American clinic. This price difference may reflect regulatory restrictions that prevent U.S. providers from expanding cells. It may also reflect the therapeutic approach used by the clinic, as well as the quality of their expertise.

In Mexico, where certain types of stem cell expansion are allowed that are restricted within the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes peripheral blood from a patient can cost as little as $1,000. In contrast, protocols that utilize more invasive sources of stem cells can run as much as $15,000 $35,000. Examples of invasive procedures includebone marrow and adipose tissue extraction. In some cases, hospitalization may be required, which raises costs. The location of a stem cell facility can factor heavily into thecost of the procedure.

Not every cost associated with treatment gets billed to the patient at the time of the procedure. Hidden costs such as reactions to the treatment, graft-versus-host disease, or disability derived from the treatment can all result in more money to the patient, to insurance, or to the government.

For example, in the case of someone with cancer, it frequently isnt viable to harvest the patients own stem cells because they may contain cancerous cells that can reintroduce tumors to the body. Instead, the patient would receive stem cells by transplant. Treatments that involve cells from another person are called allogeneic treatments. The danger here is that the body may see those cells as invaders and attack them via the immune system, a condition known as graft-versus-host disease (GvHD). The body (host) and the introduced stem cells (graft) then battle rather than coexist.

Transplanted cells often face the risk of being rejected by their host; this article discusses the effect of plasma exchange on acute graft vs. host diseasehttps://t.co/cA3nzFntew

Katie Bunde (@kbuns76) May 29, 2018

In addition to making the stem cell treatments less effective or ineffective, GvHD can be deadly. Roughly30 to 60 percent ofhematopoieticstem cell and bone marrow transplantationpatients sufferfrom it, and of those, 50 percent eventually die. The hospital costs associated with it are substantial.

Another hidden cost is the potential to disrupt a system that formerly functioned adequately. The best current example of this isthe case of Doris Tyler, who received bilateral stem cell injections in her eyes from Drs.RobertHalpernand JamieWalraven of Stem Cell Center of Georgia. According to her, while her vision was failing, it was still good enough to perform various tasks, and now it is not. That means the cost increases for her, as well as potential insurance or disability claims (though again, insurance is unlikely to cover the specific consequences of this action).

Because of tight regulations surrounding stem cell procedures performed in the United States, many stem cell treatment providers provide both on-shore (U.S.-based) and offshore (international) treatment options.Depending on where a treatment is received, patients may have to pay travel, lodging,and miscellaneous expenditures.

For example, Regenexx offers treatments at a wide range of U.S. facilities using non-expanded stem cells. However, it also offers a laboratory-expanded treatment option at a site in the Cayman Islands, which can administer higher cell doses to patients by expanding the cells in culture within a laboratory.

Similarly, Okyanos (pronounced Oh key AH nos) offers treatments to patients at its Florida location and provides more involved stem cell procedures at its offshore site inGrand Bahama. It was founded in 2011 and is a stem cell therapy provider specializing in treatments for congestive heart failure (CHF) and other chronic conditions. It is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Similarly, Celltex is headquartered in Houston, Texas, but offers stem cell treatments in Cancun, Mexico. Celltex specializes in storing a patients mesenchymal stem cells (MSCs) for therapeutic use.

While no hard evidence yet points to stem cell clinics raising their rates as a result of lawsuits, that is a typical response in industries whose products or services the public perceives as a high risk.

An additional danger to stem cell treatment providers,points out Nature, is the reduction of bottom-line profits through former patients winning suits. If clinics have to pay out the money they earned and then some to individuals suing for damages, they may soon become faced with an unviable business model. That is a definite concern for those hoping to leverage these treatments now and in the future.

As with any other area of medicine, patient evaluations of stem cell providers and treatments run the gamut from extremely satisfied to desolately unhappy. Those like Doris Tyler who have lost their eyesight exist at the negative end of the spectrum. However, many others praise stem cell treatments for their power to heal diseases, boost immunity, fight cancer, and more.

For example, BioInformants Founder and President, Cade Hildreth, had a favorable experience with stem cell therapy. Cade had bone marrow-derived stem cells collected and then had them re-injected into the knee to treat a devastating orthopedic injury. Cade was able to reverse pain, swelling, and scarring to reclaim an elite athletic ability.

As of now, this much is clear. There exists enough interest in America and across the world that stem cell providers are continuing to offer a wide range of treatments. Stem cell treatments also offer the potential to reverse diseases that traditionally had to be chronically managed by drugs. Like most medical practices, stem cell treatments will require further testing to reveal merits and faults. Until then, the public will likely continue to pursue services when medical needs arise.

Although the cost of stem cell therapy is pricey, some patients choose to undergo the treatment because it is more economical than enduring the costs associated with chronic diseases.

Although most stem cell therapy providers do not provide FDA-approved procedures, the Food and Drug Administration (FDA) continues to encouragepatients to pursue approved therapies, even if there is a higher associated treatment cost.

Providers rarely post their prices for stem cell treatments in print or digital media because they want patients to understand the benefits of therapy before making a price decision. Additionally, the price of stem cell treatments varies by condition, the number of treatments required, and the complexity of the procedure, factors that can make it difficult for medical providers to provide cost estimates without a diagnostic visit for the patient. However, in many cases, it is not in the patients best interest to make treatment decisions based on the cost of stem cell therapy. The best way to know whether to pursue stem cell therapy is to explore patient outcomes by condition and compare the healing process to other surgical and non-surgical treatment options.

The cost of stem cell therapy is indeed expensive, especially because the procedures are rarely covered by health insurance. However, with the right knowledge and a clear understanding of the treatment process, the risk of undergoing stem cell therapy can be worth it, especially if it removes the requirement for a lifetime of prescription medication. Although stem cell therapy has associated risks, it has improved thousands of lives and will continue to play in a key role in the future of modern medicine.

Download this infographic for your reference:

Are you seeking a stem cell treatment? If so, we have partnered with GIOSTAR to help you acccess medical guidance and advice.

In alignment with what we believe at BioInformant, GIOSTARs goal is to offer cutting-edge, extensively researched stem cell therapy options designed to rejuvenate and improve a patients quality of life.

Click here to Schedule a Consultation or ask GIOSTAR a question.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Do you think the cost of stem cell therapy is too much? Share your thoughts in the comments section below.

Up Next: Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research

Cost Of Stem Cell Therapy And Why Its So Expensive

Go here to see the original:
The Cost Of Stem Cell Therapy And Why It's So Expensive ...

Stem Cell Therapy Specialist – Columbia, MO: Renova …

Stem cell therapy is the latest form of regenerative medicine. It is a non-surgical minimally invasive treatment that uses human tissue for healing. With the use of umbilical cord derived stem cells and growth factors, you can treat chronic and degenerative diseases that hinder you from living life to the fullest. It can treat osteoarthritis or sports Injuries to promote faster healing via injections in joints for shoulders, knees, elbows, or where needed. Stem cells have also show promise in many chronic inflammatory disorders, neurodegenerative disorders, and autoimmune diseases.

Stop covering up your pain, let the body heal itself

Using umbilical cord stem cells, its components include growth factors, anti-inflammatory cytokines, cellular scaffold molecules and mesenchymal cells. The tissue is processed to maintain the cushioning and protective integrity. It is then injected into the joints to help naturally stimulate collagen and the healing process. With this regenerative medicine, you can promote the reparative response of diseased, dysfunctional or injured tissue.

Conditions that stem cells treat:

Benefits

Stay in your prime all the time

Stem cells are the building blocks from which all repair, regeneration, and healing of the body arise. When umbilical cord stem cells flow abundantly through the bloodstream, they reach every organ and become whatever type of cell is needed to maintain the health of each one. A higher rate of stem cell circulation goes beyond the improvement of external signs of aging. Anti aging treatment thought stem cell therapy permeates deeply and throughout the body.

Schedule your consultation now and see what treatments can give you benefits for a better tomorrow. Call 573-234-1367 or make your appointment online to see if youre a candidate for care.

Chronic conditions treated with stem cells

Stem cells effect internally

Stem cells effect externally

Is It Safe?

Umbilical cord Stem Cell Therapy is safe and effective because it doesnt run the risk of adverse reactions when the body detects something foreign as with a cellular product like stem cell derived from amniotic fluid.

Inflammation stage - lasts for 2-3 days. Fibroblasts and inflammatory mediators are recruited to the site and break down old cells.

Regenerative stage - lasts for several weeks. This is the time when new collagen is stimulated by growth factors, cytokines and stem cells.

Remodeling stage - lasts for months. In this stage, the production of new collagen continues and strengthens the skin, filling in fine lines and wrinkles. Skin tissue is regenerated and rejuvenated, resulting in a smooth and youthful appearance.

Benefits

Anti Aging Benefits inside

Anti aging treatment infuses the body with a fresh supply of pluripotent MSCs which go to work repairing and rejuvenating all organs, including the skin. Internal effects can include:

Anti aging benefits externally

SIDE EFFECTS

We use umbilical cord stem cells derived from healthy baby and mother after a healthy birth. This provides the lowest side effect profile and eliminates any allergic reaction. Some patients have reported little to no pain, swelling, or warmth at site of injection.

CLICK to learn more about Stem Cell Therapy and Regenerative Medicine.

Visit link:
Stem Cell Therapy Specialist - Columbia, MO: Renova ...

Pluripotent Stem Cells – Stemcell Technologies

Pluripotent Stem Cells

Few areas of biology currently garner more attention than the study of human pluripotent stem cells (hPSCs). This interest has arisen because of their potential to form the basis of cellular therapies for diseases affecting organ systems with limited regenerative capacity, to provide enhanced systems for drug screening and toxicity testing as well as to gain insight into early human development. There are currently two major methods for generating cells with pluripotent properties. The first involves isolating the inner cell mass from an early human blastocyst and culturing the resulting cells in appropriate culture conditions (see below) to generate human embryonic stem cells (hESCs).1 The second involves artificially expressing key developmental transcription factors in somatic cell types, which, with the appropriate culture conditions, causes the cells to be reprogrammed into induced pluripotent stem cells (iPSCs).24

Much effort has been dedicated to understanding the transcriptional state of undifferentiated pluripotent stem cells. For example, OCT-3/4,5 KLF-4, SOX2,6 and NANOG7,8 have been shown to be central to the specification of pluripotent stem cell identity due to their unique expression patterns and their essential roles in early development. These efforts, along with others, enabled the discovery of defined factors for the reprogramming of somatic cells. The specific molecular processes by which somatic cells are reprogrammed into pluripotent stem cells are not understood, although recent findings suggest it is a stepwise process,9,10 and that the stochastic nature of reprogramming can be explained in part by the multiple molecular and genetic events required for full reprogramming to occur.11 Current research focuses on improving reprogramming efficiency by better understanding several variables in the process of reprogramming: (1) the choice of factors used; (2) the delivery methods; (3) the target cell type; (4) the timing and levels of factor expression; and (5) the culture conditions. In addition to this, methods to identify and characterize truly reprogrammed pluripotent cells are also important.12

The original cocktail of factors described by Yamanaka13, OCT4, SOX2, c-MYC and KLF-4, continue to be the major factors that are used for reprogramming. Originally, delivery of the factors was achieved through the use of viruses that integrated into the genome. However, concerns over the clinical use of these cells and the potential for insertional mutagenesis have led to the exploration of non-integrating methods of factor delivery including transient transfection,14 non-integrating viral approaches15 and protein transduction.16 Other recent methods such as the use of polycystronic minicircles,17 synthetic mRNA,18 self-replicating RNA,19 RNA based viruses such as Sendai,20 and synthetic microRNA21 have also been shown to be successful. Particularly exciting are recent research efforts to identify small molecules that replace some of these factors by either modifying genome methylation patterns or inhibiting key signaling pathways.22,23 The ultimate goal of this research is to define stepwise protocols by which cells can be fully reprogrammed solely by chemical means.

The choice of cell type to use for reprogramming is based on accessibility of tissue samples, genetic make-up of the target cells, and reprogramming efficiency. Skin-derived dermal fibroblast cells and peripheral blood cells are the most commonly used cell types due to the limited invasiveness of sample collection and availability of banked tissue samples representing a variety of diseases. Peripheral blood cell types have varying and often reciprocal efficiencies of reprogramming versus frequency in blood. For example, CD34+ hematopoietic stem and progenitors have relatively high reprogramming efficiencies24 but are rare in circulating blood (0.01-0.1%).25 In contrast, T- and B-cells are more frequent and have acceptable reprogramming efficiency,26 but are less ideal as target cells for reprogramming due to TCR and IgG gene rearrangements that may affect the downstream function of hiPSCs generated from them.27 Thus, peripheral blood represents a promising and readily available source of cells for reprogramming.

Interestingly, not all cell types require all four factors to be delivered in order to successfully reprogram cells. For example, as neural stem cells endogenously express SOX2, KLF-4, and c-MYC, they were able to be reprogrammed solely through transduction of OCT-4.28 Cell types also appear to have different reprogramming efficiencies. In mice, stomach and liver cells appear to be reprogrammed more efficiently and completely than fibroblasts.29 Similarly, the reprogramming of human adipocytes is ~20-fold more efficient than fibroblasts and have the added advantage of being a readily available source of cells.30,31 As a final consideration when choosing a starting cell type, several reports have noted retained gene expression from the parental cell types32 and have also shown that the epigenetic state is predictive of the original somatic cell type.33 Such epigenetic memory may increase the propensity of iPS cell lines to differentiate to the original cell lineage/type.33-35

A common phenomenon observed during reprogramming is the emergence of partially reprogrammed colonies which are usually associated with continued expression of the reprogramming factors. These cells exhibit a range of phenotypes but often fail tests of fully pluripotent cells.37 Chan et al.38 showed that while overall reprogramming efficiency was lower in feeder-free conditions, the only types of cells that emerged were fully reprogrammed cells. This indicates the importance of culture conditions in the process of reprogramming. We developed feeder-free, defined and xenofree media for reprogramming fibroblasts (TeSR-E7) or blood cells (ReproTeSR), which provide recognizable hiPSC colonies with less differentiated or partially reprogrammed background cell growth.

Initial methods to culture hESCs were modeled on techniques originally developed to culture mouse ESCs (mESCs).39,40 These techniques involved culture on a layer of mitotically inactivated mouse embryonic fibroblasts (MEFs, or feeder cells) in medium supplemented with 20% fetal bovine serum (FBS). In these conditions, hESC lines could be propagated indefinitely with retention of their pluripotent properties.1 From the initial development of these culture conditions, it was realized that the continued use of feeders and animal-derived components in hESC cultures would hinder the development of clinical applications due to: a) the presence of immunogenic material; b) the risk of transmitting animal virus or prion material; and c) difficulty with quality control of these undefined components.

Subsequently, improvements to these procedures have largely focused on removing the undefined and non-human components. Several groups have developed culture conditions for hESCs that are, to various degrees, serum- and MEF-free. It was discovered that, in MEF-dependent conditions, serum could be replaced with Knock-Out Serum Replacement,41 a commercially available serum substitute. Xu et al. reported a culture system that utilized Matrigel as a culture matrix and MEF-conditioned medium (consisting of serum replacement and basic fibroblast growth factor, bFGF) that allowed hESCs to be cultured without direct contact with feeders.42 Another approach to MEF removal from the culture system was to replace them with human feeders.43 As the feeders are of human origin, the possibility of the transmission of foreign pathogens is limited, but unfortunately the secreted factors are still undefined and subject to large variation between batches.

True feeder-free culture has been achieved using an extracellular matrix surface coating on the cultureware, and a combination of transforming growth factor- (TGF-) and bFGF or high levels of bFGF alone44,45 together with a serum replacement in the medium. A number of publications have described defined xeno- or feeder-free media formulations for the maintenance of hESCs.46-49

The TeSR family of defined and serum-free media for feeder-free culture of hPSCs includes mTeSR1, TeSR2, and TeSR-E8. mTeSR1 was developed by Dr. Tenneille Ludwig and colleagues at the WiCell Research Institute (Madison, WI) and supports longterm, feeder-free culture of hESCs and hiPSCs.49 The formulation of mTeSR1 includes key factors that support pluripotency including bFGF, TGF-, -aminobutyric acid (GABA), pipecolic acid and lithium chloride, as well as bovine serum albumin (BSA). mTeSR1 is now the most widely-published feeder-free medium, used in over 800 peer-reviewed publications. TeSR2 is a more defined medium, based on the xeno-free formulation from the same group, containing recombinant HSA.47 The WiCell Research Institute also developed a low protein, highly defined culture medium for hPSCs. This medium, TeSR-E8, contains only the most essential components required for maintenance providing a simpler medium for the culture of pluripotent stem cells.

hPSCs differ at the molecular and functional level from mESCs and are considered to more closely resemble post-implantation mouse epiblast stem cells (EpiSCs). mESCs and conventional hPSCs exhibit distinct gene expression patterns and different requirements in culture.50,51 Specifically, mESCs are maintained by inhibiting MEK/ERK signaling, activating WNT signaling (by GSK3 inhibition), and stimulating with the leukemia inhibitory factor (LIF) cytokine, while hPSCs or mouse EpiSCs are cultured in FGF and Activin and are not responsive to LIF.50 Several recent studies have identified conditions capable of maintaining hPSCs in a ground state resembling mESCs as opposed to the primed state that hPSCs are traditionally maintained in.51-53

A lot of effort has focused on finding surface matrices that are more defined than Matrigel . Two of the more promising approaches are synthetic peptides chemically linked to the cultureware,54,55 and recombinant proteins that interact with specific integrins and cell adhesion molecules.56,57 A new defined surface, Vitronectin XF, was developed and manufactured by Primorigen Biosciences and has been commercially released by STEMCELL Technologies. Vitronectin XF can be used with mTeSR1 or, TeSR2 or TeSR-E8 for a xeno-free culture system.

Because of their differentiation potential, it is hoped that hPSCs may form the basis of cellular therapies where tissue damage or malfunction is severe and irreversible. Cardiovascular diseases, type-1 diabetes, spinal cord injury, and Parkinsons disease are examples of diseases where it is hoped that hPSC-based therapies will provide a cure. Techniques have been developed to differentiate hPSCs into a variety of adult cell types including hematopoietic,58-60 cardiac,61,62 neural,63-65 pancreatic,66-71 retinal pigmented epithelia72,73 and osteogenic lineages.74 However, a number of obstacles currently impede the clinical application of hPSC-based therapies. At present, only limited testing of hPSC-derived cells has been performed to ensure full maturation and functionality of differentiated cells. Furthermore, protocols for the differentiation of hPSCs to functionally relevant progeny are generally inefficient, resulting in low differentiated cell yields and contamination by other cell types as a result of aberrant differentiation. Of greater concern is the possibility of the persistence of undifferentiated hPSCs in transplanted populations which may result in teratomas.75,76

Further concerns surround the possibility of immune rejection of transplanted cells either due to the expression of different major histocompatibility complex antigens on donor cells77 or from the expression of foreign antigens as a result of culturing in animal products.78 Using patient-specific iPSCs for cellular therapies would circumvent the need for histocompatibility matching. And while the potential of rejection due to foreign animal antigens remains controversial,78,79 much effort is being devoted to developing xeno-free culture media and matrices for hPSC expansion and differentiation. STEMCELL Technologies offers the STEMdiff suite of defined and feeder-free products for efficient differentiation of hPSCs to cells of all three lineages.

Clinical application of hPSC-based therapies are moving closer towards becoming a reality. For example, the group led by Dr. Masayo Takahashi at RIKEN, Japan, recently started treating the first patients with age-related macular degeneration using autologous hiPSC-derived retinal pigmented epithelial cells. Similarly, early stage clinical trials are ongoing in the U.S. andthe E.U. by Advanced Cell Technologies to utilize hESC-derived retinal pigmented epithelial cells to treat Stargarts macular dystrophy, a degenerative eye disease that causes blindness in children. Finally, ViaCyte has recently received FDA acceptance of IND for the candidate hESC-derived beta cell replacement therapy for type 1 diabetes and will begin phase 1 clinical trials soon.

The most immediate impacts are likely to be gained from the use of hPSCs in the fields of drug development or toxicity testing. It has been estimated that the cost of bringing a new drug to market through development, clinical trials and FDA approval can be upwards of 800 million to 1.3 billion USD.80 Furthermore the number of drugs that are ultimately successful is very low, and many drugs fail at the phase II or III clinical trial stages due to unexpected toxicities, after large investments have been put into their development. Given these costs and the high risk assumed by pharmaceutical companies, there are great advantages to having access to large numbers of biologically relevant human cells for early testing and screening. hPSCs in their undifferentiated state may be useful to identify teratogenic or toxic effects of potential compounds. Incorporating compounds into defined differentiation protocols may identify candidates that potentiate or skew differentiation towards a beneficial outcome. The potential to generate large numbers of end stage cells such as neurons and cardiomyocytes will ultimately provide directly relevant cell types for drugs being developed for cardiovascular or neurodegenerative disorders. In addition, the generation of cardiomyocytes and hepatocytes may be directly relevant to toxicity measurements. Finally, disease-specific iPSCs made by reprogramming relevant cell types from patients has the potential of revealing not only fundamental biological defects but also providing potentially unlimited cells with which to investigate potential therapeutic approaches.

Read this article:
Pluripotent Stem Cells - Stemcell Technologies

ATCC-HYR0103 Human Induced Pluripotent Stem (IPS) Cells ATCC …

Complete Growth Medium

ATCC iPSCs have been adapted to feeder- and serum-free culture conditions.

The base medium for this cell line is Pluripotent Stem Cell SFM XF/FF (ATCC No. ACS-3002) which is a ready-to-use medium for serum-free and feeder-free iPSC culture.

Cell culture dishes are coated with CellMatrix Basement Membrane Gel (ATCC No. ACS-3035) to provide a surface for the attachment of iPSCs.

Coating Procedure:

Dilute CellMatrix in DMEM:F12 to a working concentration of 150 g/mL. For instance, if the protein concentration of CellMatrix (on certificate of analysis) is 14 mg/mL, then: (4 mL) x (0.15 mg/mL)/(14 mg/mL) = 0.043 mL. Therefore, add 43 L CellMatrix directly in 4 mL cold DMEM: F-12 Medium

ROCK Inhibitor Y27632 is not necessary each time the culture medium is changed. It is required when cells are recovering from thaw on CellMatrix Gel-coated dishes containing 5 mL Pluripotent Stem Cell XF/FF medium/6-cm dish.

This protocol is designed to passage stem cell colonies cultured in a 6 cm dish, using Stem Cell Dissociation Reagent (ATCC ACS-3010) to detach the cell colonies. The recommended spilt ratio is 1:4. Volumes should be adjusted according to the size and number of the tissue culture vessels to be processed.

Lyophilized proteins tend to be hygroscopic. Bring the vial of Stem Cell Dissociation Reagent to room temperature before opening. The vial should not be cool to the touch. Once opened, the lyophilized material should be stored desiccated. The specific activity of the reagent is found on the certificate of analysis. Dissolve the appropriate amount of Stem Cell Dissociation Reagent in DMEM: F-12 Medium to prepare a 0.5 U/mL working solution.

Note: Addition of ROCK inhibitor has been shown to increase the survival rate. The use of ROCK inhibitor may cause a transient spindle-like morphology effect on the cells. However, the colony morphology will recover after subsequent media change without ROCK inhibitor.

For optimal results, cryopreserve stem cell colonies when the cell cultures are 80% confluent. This protocol is designed to cryopreserve stem cell colonies cultured in a 6 cm dish.

Read the original here:
ATCC-HYR0103 Human Induced Pluripotent Stem (IPS) Cells ATCC ...

Induced Pluripotent Stem Cells Market Report Research …

Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of damaged tissues in the human body. An induced pluripotent stem cells, or iPSCs, are taken from any tissue (usually skin or blood) from a child or an adult and is genetically modified to behave like pluripotent stem cells or embryonic stem cells. iPSCs market is in emerging state mainly due to its ability to make any cell or tissue the body might need to encounter wide range of diseases like diabetes, spinal cord injury, leukaemia or heart disease, these cells can potentially be customized to provide a perfect genetic match for any patient. In 2018, the global Induced Pluripotent Stem Cells market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Induced Pluripotent Stem Cells status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Induced Pluripotent Stem Cells development in United States, Europe and China.

The key players covered in this study Fujifilm Holding Corporation Astellas Pharma Fate Therapeutics Bristol-Myers Squibb Company ViaCyte Celgene Corporation Aastrom Biosciences Acelity Holdings StemCells Japan Tissue Engineering Organogenesis

Market segment by Type, the product can be split into Hepatocytes Fibroblasts Keratinocytes Amniotic Cells Others

Market segment by Application, split into Academic Research Drug Development And Discovery Toxicity Screening Regenerative Medicine

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Induced Pluripotent Stem Cells status, future forecast, growth opportunity, key market and key players. To present the Induced Pluripotent Stem Cells development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Induced Pluripotent Stem Cells are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

View post:
Induced Pluripotent Stem Cells Market Report Research ...

Stem Cell Therapy Kennewick Medical Center

Until recently, treatment options for people with degenerative conditions were limited. Not many years ago, steroid injections, prescription medications, and joint replacement surgeries were often the only treatment options offered to patients. Now, in Vancouver, Washington, you can receive stem cell injections at Pain Relief Partners! Research shows that stem cell treatment is beneficial for osteoarthritis, neuropathy, chronic pain, disc bulge and herniation, spinal stenosis, joint pain, and symptoms associated with autoimmune disorders, fibromyalgia, neurodegenerative diseases, and COPD. Stem cell injections work with the bodys natural ability to heal itself. Unlike treatments that simply address the symptoms, stem cell therapy actually promotes repair of the body, restoring degenerated tissue.

After much consideration of the many products available on the market, our team has chosen to use Whartons Jelly Umbilical Cord Matrix because it contains mesenchymal stem cells, hyaluronic acid, growth factors, proteins, and cytokines all of which work together to decrease inflammation and RESTORE and REGROW damaged bone, ligament, tendon, tissue, blood vessels, and nerves. This therapy fits well with the integrated approach to wellness that we that we use for all of our treatments at Pain Relief Partners. We seek an approach to overall wellness, addressing the source of issues, rather than just treating symptoms.

Read the rest here:
Stem Cell Therapy Kennewick Medical Center

Stem cell market: Inside California’s flourishing for …

The Miracle Cell

Part 1

Part 2

Part 3

Part 4

About Stem Cells

Patients

Patient Jon Brandstad is prepared for a stem cell procedure at Health Link Medical Center in San Rafael. Gabrielle Lurie, The Chronicle

Merchants of hope

Their costly, unproven treatments can be risky. But for-profit stem cell clinics are flourishing.

Aug. 2, 2018

In the waiting room of Mark Bermans Beverly Hills office, the reception counter is crowded with trophies. Mostly made of clear plastic or glass, resembling a row of miniature ice sculptures, they are touchstones of his long career in cosmetic surgery.

For more than three decades, Bermans focus was breast augmentations and face-lifts. He invented a pocket-like device that can be implanted into the breast to produce better-looking, safer results from augmentation procedures. He calls it his Sistine Chapel.

The Miracle Cell

This series explores the hope and reality of the revolutionary science of stem cell therapy. It focuses on what has transpired since 2004, when California voters approved a $3 billion bond measure to fund stem cell research with the promise that it soon would produce new treatments for incurable diseases.

In four parts, it follows the stories of patients desperately seeking remedies; probes the for-profit clinics where unproven and unregulated treatments are being offered; takes you into the labs and hospital rooms where scientists are testing new therapies; and provides a comprehensive accounting of what Californias multibillion-dollar bet on stem cells has achieved.

But over the past eight years, Berman has reached far past his specialty into a realm of highly sophisticated, still-nascent medicine. Hes become one of the countrys most outspoken and notorious providers of so-called consumer stem cell therapies: using human stem cells to treat a wide variety of ailments despite little or no scientific proof that they work.

With his business partner, Rancho Mirage (Riverside County) urologist Elliot Lander, Berman has built the largest chain of stem cell clinics in the country. Their Cell Surgical Network has more than a hundred affiliatesin 33 states including 38 clinics in California alone selling treatments they claim will fix everything from knee pain to symptoms of multiple sclerosis.

As a cosmetic surgeon, its kind of a joke that Im at the center of this universe, Berman said in an interview last fall. But Im kind of ground zero.

Seven months later, his words became darkly prophetic: In May, Berman and his partner were targeted by the U.S. Food and Drug Administration. The FDA requested an injunction that, if approved by a federal judge, would stop them from selling stem cell therapies.

The FDA issued a similar request against a separate operation in Florida, U.S. Stem Cell Clinic.

Their clinics, though, are just some among several hundred that havepopped up across the country in recent years. They are renegade outposts operating with little legitimacy and oversight at the frontier of what is otherwise a highly promising field of medicine.

The allure of stem cells is powerful. Taken from human tissue, they are defined by their ability to transform themselves into most any other type of cell and to replicate over and over far beyond the limits of mature, fully formed cells that dont change and cant reproduce. Stem cells could be used to replace cells in the heart, lungs, bones and brain, to heal a body damaged by disease, injury or aging.

The extraordinarypotential ascribed to stem cells has captivated scientists around the world, some of whom have devoted entire careers to studying them. In 2004, California voters were so convinced of their promise that they approved a $3 billion bond measure to pay for research into them.

Its that sense of possibility that consumer clinics have tapped into. But the stem cells they are selling and those the worlds top scientists are studying are not the same.

None of the treatments the clinics offer have been shown to be safe or effective. None have been approved by the FDA. Theyre not backed by decades of laboratory and animal studies or by rigorous testing in humans.

Yet for many patients desperate for care, these clinics fill the void between the long-anticipated potential and the real-world limitations of stem cells. They cater to people whose needs reach beyond the powers of current medicine people who want to believe in the almost mythic powers of stem cells, who feel corporate health and science have forsaken them.

People who turn instead to these merchants of hope.

For-profit stem cell clinics have come under attack from mainstream scientists and doctors, from disgruntled and disappointed patient-customers, from the FDA and other regulatory agencies. Yet they have managed to thrive.

Theres no registry of these clinics, no licensing authority at the state or federal level, no way to know exactly how many exist. A recent reporton the industry offers one measure: In 2008, there were no U.S. clinics marketing stem cell therapies online. By 2010, it found, there were about a dozen. In 2016, there were at least 570, according to a paper published in Cell Stem Cell.

That number has almost certainly increased since. The authors of the report UC Davis scientist Paul Knoepfler and University of Minnesota bioethicist Leigh Turner believe there are now 700 or more consumer stem cell clinics in the United States, and that up to 20,000 people have undergone their treatments.

There are hubs in Florida and parts of Texas, their report says, but a fifth of the clinics are located in California. Clusters of them operate in Los Angeles and San Diego. Bermans is one of eight or more clinics located along a 1-mile strip in Beverly Hills, among the Hermes and Louis Vuitton boutiques.

The Bay Area is home to at least a dozen such clinics, a simple online search shows. More are located in Monterey, Sacramento and Redding. About half ofthe Northern California clinics specialize in treating chronic pain, orthopedic issues or sports injuries. Others claim to treat complex neurological and immune conditions.

The providers are usually, though not always, licensed doctors, but they often are working far outside their fields of expertise. They advertise on social media and in newspapers. They host seminars and online lectures. Many promote therapies that federal guidelines plainly state are not allowed.

Some clinic websites list the illnesses and injuries they claim to treat in neatly categorized drop-down menus. One shows a diagram of a man not unlike the patient in the old board game Operation, with arrows pointing to his knees, shoulders, feet, eyes, heart and brain. The Stem Cell Revolution, a book by Berman and Lander, lists 47 conditions they say they or their colleagues can treat.

High-end shopping, luxury salons and stem cells

Beverly Hills appears to be home to the largest cluster of for-profit stem cell clinics in the United States. In an area along a one-mile stretch of Wilshire Boulevard, bisected by the world-famous Rodeo Drive, at least eight stem cell clinics operate. At one end of Wilshire is the office of Cell Surgical Network founder Mark Berman, and at the other is the clinic of Nathan Newman, a cosmetic surgeon who specializes in stem cells for face-lift procedures. The Beverly Hills clinics are pressed between juice bars, jewelry boutiques and posh outlets of international brands like Hermes and Louis Vuitton along with organic pharmacies, day spas and many plastic surgery offices.

Nathan Newman, a cosmetic surgeon in Beverly Hills, uses stem cell therapy to treat a patient with facial disfigurement. Manjula Varghese, The Chronicle

These clinics work with what are known as adult stem cells, usually harvested from tissue taken from a patients own body and returned by injection. Patients are told that their very own cells can treat almost any ailment and can do more for their health than drugs or surgeries that have already failed.

Its a promise that resonates with Baby Boomers resisting old age, with a generation of younger patients with chronic, sometimes fatal, diseases who are running out of time, and with a broader American population that is impatient and empowered when it comes to managing their health care.

The cost of a single treatment typically ranges from about $2,000 to $20,000, though it can be much higher, according to informal patient surveys that Knoepfler has done. Often several treatments are recommended. These therapies are not covered by insurance and many clinics promote payment plans on their websites. Thousands of patients have turned to crowdfunding websites sharing heartbreaking stories of chronic illnesses, fatal diagnoses and devastating injuries in their requests for money to pay for stem cell treatments.

A woman walks by a Dior advertisement on Rodeo Drive. Among the clothing stores and handbag boutiques in swanky Beverly Hills are several stem cell clinics. Scott Strazzante, The Chronicle

Reports have emerged of some terrible outcomes related to commercial stem cell therapy cases of people who have been blinded or whose conditions deteriorated after they were treated. One man developed tumors after multiple stem cell treatments. Several people who sought stem cell therapies overseas have died. But the full extent of risks from these therapies is unknown, because no one organization tracks them.

The California Institute for Regenerative Medicine the state agency created by Proposition 71 in 2004 to fund stem cell research has raised concernsabout the thriving consumer therapy market. CIRM officials and many of the scientists they fund worry that the selling of unproven treatments could undermine their own work and cast doubt on the enormous potential of regenerative medicine.

But until the recent FDA complaints, enforcement of federal guidelines on appropriate use of stem cells had been scarce, say critics of the for-profit industry. The guidelines themselves were formalized only last November years after critics had raised warnings about the risks consumer clinics posed.

Some ofthese places, theyre very much just focused on the profit. Some of them are just rebels. But some of them, do they genuinely believe in stem cell magic? said Knoepfler, a professor of cell biology and human anatomy at UC Davis. Whatever motivates them, it hardly matters, he said.

Patients need to approach all of them with skepticism, he said. I get it. Its hard to be patient. I understand if youre miserable, if youre partially paralyzed or have debilitating arthritis or youve had COPD for 20 years and youre looking for a game-changer. But if something sounds too good to be true, it probably is.

Mark Berman has thick, highly styled, slate-gray hair, and at the end of a midweek day, his navy blue scrubs are crisp and neat.He keeps a sample of the breast-pocket device and a copy of his stem cell book at hand in his office. On his desk is a sculpture of a dragon, his Chinese zodiac sign. Dragons, its said, are hot-headed, intelligent, risk-taking.

An animated conversationalist, Berman speaks with a kind of relaxed confidence thats both charming and intimidating. Its easy to understand why some people are eager to trust him, and others more apt to doubt.

From memory, he recitespatient testimonials and notes lab and animal studies that he says support his work in stem cells. He claims that he and his colleagues have successfully treated people with multiple sclerosis and Alzheimers disease, brain injuries and bum knees. His wife benefited from stem cell injections in her hip, he said. Hes treated himself for sciatica.

The work, he says, fills him with an enthusiasm he hasnt experienced since his earliest days out of medical school. He sees himself as a pioneer in a field thats just blossoming, and will transform the practice of medicine.

Mark Berman is co-founder of California Stem Cell Treatment Center and the Cell Surgical Network. Scott Strazzante, The Chronicle

That field has come to be known as regenerative medicine, so called because it focuses on rebuilding the body to heal damage done by illness and injury. Scientists have long thrilled to the concept, but only in the past couple of decades have any strides toward actual therapies been made.

Theoretically, stem cells could be used to replace cardiac muscle damaged in a heart attack, nerve cells destroyed by spinal cord injury, bone and cartilage wasted with age. Mainstream doctors and scientists say that and more is possible someday, with the right kind of stem cells, under the right circumstances. The right kind of stem cell, though, is not whats being sold in consumer clinics.

Berman, along with almost all providers at for-profit clinics, uses autologous adult stem cells autologous meaning they come from a patients own body. Unlike embryonic stem cells, which build every part of a developing human body, adult stem cells are limited in their abilities.

Embryonic stem cells, along with laboratory-generated induced-pluripotent stem cells, can turn into every other kind of cell and regenerate themselves endlessly. Adult stem cells can turn only into certain types of cells and will eventually stop replicating. They are found in pockets in bone marrow or in certain organs, for example and develop into the types of cells found in the tissue from which they came.

Though less powerful than embryonic and induced-pluripotent stem cells, adult stem cells have advantages. They are easily accessible and relatively cheap to obtain. There is evidence that certain adult stem cells may act as potent anti-inflammatories, say some scientists.

Adult stem cells also are less controversial than embryonic stem cells, which come from embryos that are destroyed during the process of isolating them. Some of the top stem cell experts in the world believe that adult stem cells may be better suited for certain therapies than embryonic stem cells.

A doctor at Health Link Medical Center in San Rafael holds syringes filled with stem cells. The stem cells, taken from a patients bone marrow, are ready to be re-injected into the patient. Gabrielle Lurie, The Chronicle

Paul Handleman (left) works with nurse Jessica Vanderbyl during a stem cell procedure at Health Link Medical Center. Health Link is part of Regenexx, a Colorado-based operation that specializes in using stem cells for orthopedic procedures. Gabrielle Lurie, The Chronicle

But those same experts say that prospect is years, if not decades, away. Berman says its already here.

He and other for-profit providers say adult stem cells can home in on damaged parts of the bodyand perform different healing functions. In the eye, they say, stem cells can help replace the light-sensing rods and cones damaged by disease. For a systemic illness like multiple sclerosis, in which an overactive immune system attacks the bodys own nerve cells, stem cells can help rebuild damaged cells and improve immune function, they say.

These claims if theres any evidence for them at all usually are based on laboratory studies of cells in Petri dishes, not on controlled tests on animal or human subjects. Proof that stem cells can actually help people is almost always anecdotal.

Scientists performing the most rigorous research say that what Berman and other for-profit providers suggest is not possible. Adult stem cells taken from fat the technique Berman uses cannot replace cells in the eye. They wont target an injured area of the brain. They wont float around the body healing the immune system.

Sign up to be notified when we release future installments of this story.

To critics, Berman said, Were a bunch of quacks and scallywags ... were charlatans and taking advantage of people.

Thats ridiculous, he said. Why would I be doing this unless it was incredibly successful?

Critics point to one answer: money.

Procedures at Bermans clinics cost $8,900, though he said hell reduce or waive costs for patients in need. He and Lander also charge doctors who join their network about $30,000 for training and equipment, including a device they call the time machine a reference to stem cells fabled ability to reverse the effects of aging to make the product they use in treatments.

Berman said he understands the value of rigourous, long-term research to test the safety and efficacy of new therapies. But hes convinced that what hes selling is already helping people. And if hes able to offer a treatment now, even if its imperfect, thats our moral duty, he said.

Were taking people with absolutely no chance, and were giving them a little hope.

In the medical realm, the notion of hope can be divided broadly into two categories: the probable and the possible.

Mainstream medicine is largely based on the probable what science has shown is the likely outcome of illness or injury and the treatments applied. Probable hope is based on statistics, evidence and careful analysis.

Possible hope, by contrast, is more what if? If probable hope says a treatment is 99 percent likely to fail, possible hope says: What if I am the 1 percent?

Nathan Newman examines patient Hersel Mikaelian in his Beverly Hills clinic. Newman, who specializes in using fat stem cells for cosmetic procedures, treated Mikaelian for facial disfigurement caused by cancer. Scott Strazzante, The Chronicle

The providers of consumer stem cell therapies operate largely in this latter domain. Its a model of care that feeds on the irresistible desire of most people to hope for the best to believe that they will be the one for whom an untested, unproven treatment will work.

Most patients, and their loved ones, their families, theyre operating on this model in which anything is possible, said the Rev. Peter Yuichi Clark, director of spiritual care services at UCSF. Medical advances are happening every day. Maybe there will be a treatment that responds to my particular condition.

Hopedrove Auburn resident Katie Gwinn through six stem cell treatments that cost her more than $100,000.

She got her first treatment in 2013, at a clinic in Panama thats become a destination for people with certain conditions, particularly multiple sclerosis and autism. Gwinn has MS, and though the disease progressed slowly at first, by 2010 shed had to stop working due to fatigue and pain.

She was only 54 at the time and not ready to consider herself permanently disabled. But drugs that were supposed to slow down progression of the disease didnt seem to be working. She was tired all the time. Her right leg was stiff and hard to move.

Online, Gwinn found the Stem Cell Institute in Panama City, which uses adult stem cells taken from donated umbilical cord tissue. After her first treatment, she felt like she had more energy. Her right leg was stronger, her limp less noticeable. But after eight or nine months, the benefits faded. When she repeated the therapy a year and a half later, the results were less impressive. Each treatment cost her nearly $20,000.

Gwinn then found another clinic, StemGenex, in San Diego. The doctors there said they would treat her with stem cells extracted from her own fat. It was cheaper: $15,000, and she wouldnt have to travel to another country.

But after her visit there in 2015, she didnt notice any change in her condition. I was extremely disappointed, she said.

Ultimately, she would return to Panama for three more treatments, but finally decide that whatever slim benefits she received werent worth the cost.

Shes 62 now and on a new drug, approved by the FDA in 2016, that slows progression of MS in some patients. Her doctor said they should know by the end of this year if its working for her.

In hindsight, she realizes the therapy she got in San Diego was not going to work. The doctor who treated her had a background in cosmetic surgery, and no formal training in multiple sclerosis. Shed been overly hopeful. Desperate.

It was a plastic surgeons office, Gwinn said. They were just taking out the cells and spinning them around and putting them right back in. What theyre doing for MS is not a darn thing.

Still, she says she doesnt regret the time and expense she invested. It was a costly foray into the limits of hope, but one she felt she needed to make. And she hasnt entirely given up on stem cells. They might help some people, someday just probably not her.

Stephen Derrington treats patient Shannon McCloud at Health Link Medical Center, a stem cell clinic in San Rafael. Gabrielle Lurie, The Chronicle

Others are far more critical of the clinics.

Some stem cell providers may truly believe theyre helping people, said David Spiegel, a Stanford psychiatrist who is chair of the universitys advisory panel that oversees its research involving stem cells. Most, though, are well aware that what theyre selling isnt real, he said.

The idea that its this magic cure is greatly exaggerated, Spiegel said. At the moment, most of it in clinical practice is snake oil. I dont have much of a sense of humor about these practitioners and companies that are fleecing people on false hope.

The "Torso" statue by Robert Graham stands at Rodeo Drive and Dayton Way, in the center of Beverly Hills shopping district. At least eight stem cell clinics are within walking distance of the art. Scott Strazzante, The Chronicle

For every warning about unproven stem cell therapies, though, there are stories that boost their legitimacy: endorsements by satisfied customers, name-drops of celebrity patients.

San Francisco Giants pitcher Mark Melancon had been sidelined by an elbow injuryfor months, despite surgery and working with top physical therapists. In April, he had stem cells injected into the injury site. Doctors didnt claim the treatment would cure him, but hoped it would speed his recovery.

Two months later, just about the time the team had expected after surgery, he was back on the mound.

The doctor who recommended the stem cells James Andrews, of the Andrews Institute in Florida says he has done similar therapy with hundreds of professional athletes. And its not just current athletes crowing about stem cells. Golf legend Jack Nicklaus credited a stem cell therapy in helping him recover from a post-career injury. The family of hockey star Gordie Howe claimed stem cells helped prolong his life after a stroke; he died in 2016.

Testimonials by patients and their families, often featured prominently on clinic websites, are especially powerful lures to prospective clients. In a video made for the Panama clinic that Gwinn visited, actor Mel Gibson says that his 93-year-old fathers quality of life improved dramatically after being treated there. Other clients share stories of miracle recoveries, of feeling better than they have in years.

The suggestion is clear: Stem cells healed me, and they could heal you,too. Such endorsements have helped give stem cells credence among an increasingly mainstream audience.

Its night and day for me, said Jon Brandstad, 70, a Stockton-area farmer who received stem cell injections in his left shoulder at a clinic in San Rafael two years ago.

Continued here:
Stem cell market: Inside California's flourishing for ...

FDA Wants To Tighten The Screws On Stem Cell Clinics …

By Emily Bazar September 12, 2016

The U.S. Food and Drug Administration is proposing to get tougher on clinics that offer unapproved stem cell therapies, and is hosting a critical public hearing on the issue Monday and Tuesday in Bethesda, Md.

A study published recently in the journal Cell Stem Cell found that 570 clinics across the country are offering pricey stem cell treatments for both cosmetic and medical purposes. The clinics claim to treat a wide variety of problems, from spinal cord injuries to autism.

Authors Leigh Turner of the University of Minnesota and Paul Knoepfler of the University of California, Davis identified 113 such clinics in California alone, the most of any state.

There are clear grounds for concern that some of the companies we found are not compliant with federal regulations, they wrote.

Many of these clinics say they use stem cells derived from patients own fat. They argue their treatments are exempt from the agencys rigorous approval process because the fat cells are minimally manipulated and shouldnt be classified as drugs subject to FDA regulation.

But late last year, the FDA sent a warning letter to a doctor saying that the processing of fat cells in his clinics, including one in California, would not meet the definition of minimal manipulation and his product was therefore considered a drug that required agency approval.

Nearly 100 stem cell clinics, doctors, researchers and organizations plan to testify at the hearing about these issues.

California Healthline interviewed three participants, with divergent views, all California-based experts whose professional lives revolve around stem cell science.

Jeanne Loring is a professor and stem cell researcher at The Scripps Research Institute in La Jolla. She supports tighter FDA controls.

Elliot Lander is co-medical director and co-founder of Cell Surgical Network, a Rancho Mirage, California-based group comprising about 100 stem cell clinics, most of them in the U.S. He is wary of the FDAs plan for more regulation.

C. Randal Mills is CEO of the California Institute for Regenerative Medicine, the states stem cell agency, based in Oakland. He calls for a middle ground between the FDAs strict approval process and total exemption from that process.

The transcript below has been edited for length and clarity.

We encourage organizations to republish our content, free of charge. Heres what we ask:

You must credit us as the original publisher, with a hyperlink to our californiahealthline.org site. If possible, please include the original author(s) and California Healthline in the byline. Please preserve the hyperlinks in the story.

Its important to note, not everything on californiahealthline.org is available for republishing. If a story is labeled All Rights Reserved, we cannot grant permission to republish that item.

Have questions? Let us know.

Read more here:
FDA Wants To Tighten The Screws On Stem Cell Clinics ...

Meet Our Doctors – Rejuva Stem Cell Clinic

Dr.KarenVieira has a Ph.D. in Biomedical Sciences from the Department of Biochemistry and Molecular Biology at the University Of Florida College Of Medicine, a Master of Science in Management and a Bachelor of Science in Molecular Biology. She has worked in hospitals and clinics conducting clinical research with patients, as well as in biotechnology laboratories, researching the biochemistry and molecular biology of the body, animals and even micro-organisms.This involved both mouse and human stem cell research.

Additionally, she worked in the food industry with the largest food company in America whereshe researched food and supplement ingredients for a variety of health conditions. While there, she also started a comprehensive cell culture research project, a first of its kind there, discovering and prioritizing novel and emerging food ingredients for health and wellness using cell culture studies.

Karenis the owner of The Med Writers, a company specializing in writing and consulting in the food, supplement, biotech, pharma and stem cellindustries.Her passion is discovering existing research on dietary and lifestyle changes, plus non-pharmaceutical and non-surgical methods,that prevent, cure or improve various health conditions. Not only does she have knowledge on healthy living, but she personally lives it, inspiring others to do the same.Having experienced the power of stem cell injections personally, she is an advocate for stem cells to boost health.

Most importantly, she has the rare ability to explain the findings of medical research studies in an easy-to-understand way so that anyone can instantly get it. Her knack for explaining things gives listeners and readers simple steps on how to apply and use the knowledge in their own life to improve their health. For these reasons and more, Dr. Vieira is currently a popular author, speaker and consultant in the health and wellness industry.

View original post here:
Meet Our Doctors - Rejuva Stem Cell Clinic

Cell and Gene Therapy Center – IQVIA

Developing advanced therapies involves making critical Chemistry, Manufacturing and Controls (CMC) decisions and managing complex clinical studies while navigating through an evolving regulatory and reimbursement environment.

The Cell and Gene Therapy team from IQVIA can provide the data, expertise, and services that help you transcend the challenges faced in the development and commercialization of cell and gene therapies.

Strategic and operational services customized to your therapy:

Our dedicated team of experts combine cell and gene therapy expertise with the capabilities of the IQVIA COREto address your needs throughout the development pathway.

We have a proven track record supporting a range of clients, from academics to emerging biotech and established pharmaceutical companies, in:

Comprehensive network of partners to respond to your needs:

The Cell and Gene Therapy group works in close collaboration with our alliance partners to address the unique challenges in cell and gene therapy manufacturing and nonclinical research.

Through our partnership with the California Institute for Regenerative Medicine (CIRM), we have access to the Alpha Stem Cell Clinics network that provides experienced sites for your stem-cell based therapies for more reliable and rapid study startup.

Read more here:
Cell and Gene Therapy Center - IQVIA